|
 |
European BioPharmaceutical Review
|
| As we bring you the summer issue of EBR, there appear to be guarded grounds for continued optimism towards an upswing in the European biotechnology industry. As evidenced by the upbeat mood of the US industry at the recent Annual BIO Convention, this new optimism seems to be based on tangible measures of an industry regaining its feet. For example, increasing numbers of biologic drugs (25 out of 37) approved by the FDA in 2003, coupled to decreasing product review timeframes by the FDA, led to renewed investor interest and the second most successful financing year in the US industry's history in 2003 ($19 billion in public and private funds). However, the situation in Europe isn't quite that rosy. |
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
Paediatric Clinical Trials
19-20 January 2009, Copthorne Tara Hotel, London, UK
More info >>
|
|
 |
News and Press Releases |
 |
INTERLAB growing at a rate of 35%
24th November 2008
More info >> |
|
|
